These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 8017842)
21. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645 [TBL] [Abstract][Full Text] [Related]
22. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486). Milewicz T; Gregoraszczuk EL; Sztefko K; Augustowska K; Krzysiek J; Ryś J Growth Horm IGF Res; 2005 Apr; 15(2):140-7. PubMed ID: 15809018 [TBL] [Abstract][Full Text] [Related]
23. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines]. Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630 [TBL] [Abstract][Full Text] [Related]
24. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen. Howe SR; Pass HI; Ethier SP; Matthews WJ; Walker C Cancer Res; 1996 Sep; 56(17):4049-55. PubMed ID: 8752178 [TBL] [Abstract][Full Text] [Related]
26. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Swami S; Krishnan AV; Feldman D Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825 [TBL] [Abstract][Full Text] [Related]
27. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749 [TBL] [Abstract][Full Text] [Related]
28. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892 [TBL] [Abstract][Full Text] [Related]
29. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221 [TBL] [Abstract][Full Text] [Related]
30. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents. Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397 [TBL] [Abstract][Full Text] [Related]
32. Potent inhibition of breast cancer cell lines by the isoflavonoid kievitone: comparison with genistein. Hoffman R Biochem Biophys Res Commun; 1995 Jun; 211(2):600-6. PubMed ID: 7794275 [TBL] [Abstract][Full Text] [Related]
33. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer. Leclercq G; Devleeschouwer N; Heuson JC J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875 [TBL] [Abstract][Full Text] [Related]
34. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Wimalasena J; Meehan D; Dostal R; Foster JS; Cameron M; Smith M Oncol Res; 1993; 5(8):325-37. PubMed ID: 8012064 [TBL] [Abstract][Full Text] [Related]
35. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Kleinman D; Karas M; Danilenko M; Arbell A; Roberts CT; LeRoith D; Levy J; Sharoni Y Endocrinology; 1996 Mar; 137(3):1089-95. PubMed ID: 8603578 [TBL] [Abstract][Full Text] [Related]
36. Permissive role of polyamines in the cooperative action of estrogens and insulin or insulin-like growth factor I on human breast cancer cell growth. Huber M; Poulin R J Clin Endocrinol Metab; 1996 Jan; 81(1):113-23. PubMed ID: 8550737 [TBL] [Abstract][Full Text] [Related]
37. Estrogen and insulin modulation of intracellular insulin-like growth factor binding proteins in human breast cancer cells: possible involvement in lysosomal hydrolases oversecretion. Dubois V; Couissi D; Schonne E; Schneider YJ; Remacle C; Trouet A Biochem Biophys Res Commun; 1993 Apr; 192(1):295-301. PubMed ID: 7682810 [TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Taylor CM; Blanchard B; Zava DT Cancer Res; 1984 Apr; 44(4):1409-14. PubMed ID: 6704959 [TBL] [Abstract][Full Text] [Related]
39. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer. Toko T; Shibata J; Nukatsuka M; Yamada Y Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952 [TBL] [Abstract][Full Text] [Related]
40. Antitumor mechanism of action of a cyclopropyl antiestrogen (compound 7b) on human breast cancer cells in culture. Jain PT; Pento JT; Magarian RA Cancer Chemother Pharmacol; 1996; 38(3):238-44. PubMed ID: 8646798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]